Clomiphene Drug

## What it is Clomiphene citrate is a selective estrogen receptor modulator (SERM) developed at Wm. S. Merrell in the late 1950s and FDA-approved in 1967 for ovulation induction in women with anovulatory infertility. It is structurally a triphenylethylene, related to tamoxifen, and is supplied as a roughly 38:62 mixture of two geometric isomers: zuclomiphene (cis, 38%) and enclomiphene (trans, 62%). The two isomers have different pharmacological properties, and the male-use case has driven interest in pure enclomiphene formulations. In women, clomiphene's approved use is straightforward: 50 to 100 mg daily on cycle days 5 to 9 induces ovulation in a substantial majority of anovulatory patients, typically those with PCOS or hypothalamic-pituitary dysfunction. It has been the workhorse first-line ovulation induction agent for over five decades, though letrozole has displaced it as the preferred first-line agent in PCOS following the Pregnancy in Polycystic Ovary Syndrome II trial (PPCOS-II, Legro 2014). The male use case is off-label and has grown substantially since the 2010s. In men with hypogonadism, particularly secondary (hypogonadotropic) hypogonadism in younger men with intact testicular function, clomiphene raises endogenous testosterone production by blocking estrogen-receptor-mediated negative feedback at the hypothalamus and pituitary. This is fundamentally different from TRT: instead of supplying exogenous testosterone (which suppresses the HPT axis and impairs fertility), clomiphene reactivates the axis. The result is preserved testicular size and spermatogenesis alongside elevated testosterone, which is the central appeal in men who want androgen support without sacrificing fertility. A pure trans-isomer formulation (enclomiphene citrate) was developed by Repros Therapeutics under the brand name Androxal, and underwent Phase 3 trials in secondary hypogonadism. The FDA declined approval in 2016, citing study design concerns rather than efficacy or safety failures. Enclomiphene is now widely available through compounding pharmacies in the US and is preferred over racemic clomiphene by many male-hormone clinicians because it lacks the longer-acting and more estrogenic zuclomiphene fraction. ## Mechanism of action Clomiphene is a partial estrogen receptor agonist with mixed agonist and antagonist activity depending on tissue context. At the hypothalamus and pituitary, it acts as an antagonist, blocking the negative-feedback inhibition that circulating estrogens exert on GnRH and gonadotropin secretion. The result is increased pulsatile GnRH, increased LH and FSH, and downstream stimulation of gonadal steroidogenesis. In men this means increased testicular testosterone production. In women it means follicular development and ovulation. The two isomers differ functionally. Zuclomiphene (cis) has a longer half-life (estimated 2 to 3 weeks), accumulates with continuous dosing, and exhibits more residual estrogenic activity at peripheral tissues. Enclomiphene (trans) has a shorter half-life (around 10 hours), clears between doses, and produces cleaner antagonism at the hypothalamus. The clinical pattern follows: enclomiphene produces less estrogenic side-effect burden (mood changes, visual symptoms, bloating) at equivalent testosterone effect. In women, the ovulation induction effect occurs because the antagonism at the hypothalamus during cycle days 5 to 9 mimics a low-estrogen environment, increasing FSH output, which drives follicular growth. Once dominant follicle selection occurs and the surge mechanism activates, ovulation proceeds. The 5-day-on, then-off pattern is the canonical protocol because continuous dosing in women produces unfavorable endometrial and cervical effects. In men, the dosing pattern is different. The off-label male protocol typically uses 12.5 to 25 mg daily or every other day continuously, or 25 to 50 mg three times weekly. Dose-response in men plateaus at modest doses; higher doses do not produce proportionally higher testosterone and do increase side effect burden. Pharmacokinetics of the racemic mixture: peak plasma levels at 6 to 8 hours, biphasic clearance, with the zuclomiphene component detectable in plasma for weeks after the last dose. Enclomiphene-only formulations have cleaner PK with steady-state achieved within 5 to 7 days of daily dosing. ## Evidence base by outcome ### Ovulation induction in anovulatory women A-tier. Clomiphene induces ovulation in roughly 70 to 80% of anovulatory women, with cumulative pregnancy rates of 30 to 40% over six cycles. Letrozole has higher live-birth rates in PCOS specifically (Legro 2014, n=750, 27.5% vs 19.1%) and has displaced clomiphene as first-line in PCOS in many guidelines. Clomiphene remains widely used in non-PCOS anovulation and where letrozole access is restricted. ### Endogenous testosterone elevation in men A-tier on the surrogate endpoint. Multiple trials report consistent total testosterone increases of roughly 200 to 500 ng/dL above baseline at typical male doses. Whitten 2006 (n=36 men with secondary hypogonadism, 25 mg every other day) reported total T rising from ~250 to ~600 ng/dL. Kim 2016 (n=400, retrospective) reported similar magnitudes. Wiehle 2014 (Repros Phase 3, enclomiphene 12.5 to 25 mg daily) reported sustained T elevation with preserved sperm parameters. ### Sperm parameters and fertility preservation A-tier on preservation, B-tier on fertility outcomes. Unlike TRT, clomiphene does not suppress spermatogenesis; the male trial data consistently show preserved or improved sperm concentration and motility. Idiopathic male infertility trials (Hussein 2005, Hussein 2013) have reported pregnancy rate improvements with clomiphene, but the evidence base is heterogeneous. ### Symptomatic improvement in male hypogonadism B-tier. Trials report improvements in libido, energy, and mood in men with secondary hypogonadism, though the magnitude is variable and some men report subjective benefit from the testosterone elevation while others do not. The dissociation between biochemical normalization and symptomatic improvement is real. ### Body composition in men C-tier. Small trials report modest lean-mass gains and fat-mass reductions in men with secondary hypogonadism, but the magnitude is smaller than TRT. ### Bone mineral density in men C-tier. Limited evidence; small studies report modest BMD improvements in hypogonadal men on clomiphene. ### Visual disturbances A-tier on adverse signal. The ophthalmologic side effect profile is the most distinctive aspect of clomiphene. Roughly 1 to 2% of users (more common in women on full ovulation-induction doses, less common at male maintenance doses) report blurred vision, scintillating scotomas, light sensitivity, or persistent afterimages. The mechanism is uncertain but may involve retinal photoreceptor effects. The visual symptoms typically resolve within days to weeks of discontinuation. Persistent or progressive visual symptoms warrant immediate cessation and ophthalmology evaluation. ### Multiple gestation in fertility use A-tier on signal. Clomiphene-induced ovulation produces twin pregnancy rates of roughly 7 to 10% (versus 1% in spontaneous conception). Higher-order multiples (triplets and beyond) are rare but elevated. ### Endometrial effects in women B-tier. Clomiphene produces an unfavorable endometrial environment in some users, with thinner endometrium and reduced cervical mucus quality. This is one of the reasons letrozole has displaced clomiphene as first-line in PCOS: it produces equivalent ovulation induction without the antiestrogenic endometrial effect. ## Dosage and administration Female ovulation induction: 50 mg daily on cycle days 5 to 9 for the first cycle, with dose escalation to 100 mg or 150 mg in subsequent cycles if ovulation does not occur. Six cycles is the conventional ceiling before transitioning to alternative agents. Male off-label hypogonadism: 12.5 to 25 mg daily or every other day, or 25 to 50 mg three times weekly. The male dose is roughly half the female dose because the LH/FSH stimulation goal is sustained moderate elevation rather than the cyclic surge required for ovulation. Some clinicians prefer pulse dosing on alternating days to avoid steady-state estrogen accumulation from the zuclomiphene fraction; enclomiphene formulations make this less of a concern. Enclomiphene-only formulations are typically dosed 12.5 to 25 mg daily. The cleaner PK supports daily continuous dosing without the accumulation concerns of racemic clomiphene. Monitoring: total and free testosterone, LH, FSH, estradiol, hematocrit at baseline and 8 to 12 weeks after initiation. Visual symptoms warrant immediate clinical attention. PSA monitoring in men over 40, as with TRT. No formal cycling is part of the male-use protocol. Continuous dosing for months to years is common. Some protocols include planned washouts to confirm ongoing dependence on the medication for testosterone elevation. ## Side effects and safety Most common side effects in women: hot flushes (10 to 20%), abdominal discomfort (5 to 10%), breast tenderness, mood changes, ovarian enlargement. In men: mood changes (irritability, emotional lability) are the most common discontinuation reason, particularly with racemic clomiphene; visual symptoms (~1 to 2%); gynecomastia (uncommon but reported); breast tenderness; nipple sensitivity. The mood profile in men is the dominant practical issue. The estrogenic activity of zuclomiphene at the brain produces mood changes that some men describe as 'feeling off,' with elevated emotionality, irritability, or low motivation. Switching to enclomiphene-only formulations resolves this for many users. Visual disturbances are rare but tracked. Persistent visual symptoms warrant immediate cessation. Pre-existing severe ophthalmologic conditions are a relative contraindication. Venous thromboembolism risk is theoretically a concern given the estrogen-receptor activity, particularly in patients with predisposing factors. The available data have not shown a strong VTE signal, but caution is appropriate in users with prior DVT or known thrombophilia. Ovarian hyperstimulation syndrome is rare with clomiphene (more common with injectable gonadotropins) but reported. The drug has been in clinical use for over 50 years; the long-term safety record is reassuring at the doses and durations typical of fertility use. Long-term continuous male use beyond 2 to 3 years has less safety data; clinicians should monitor for emerging concerns. Pregnancy: contraindicated. Clomiphene should be discontinued before conception is achieved. ## Stack interactions and timing In male hypogonadism protocols, clomiphene is sometimes combined with hCG (low dose) for additive testicular stimulation in men with very low baseline LH. The combination is empirical; the evidence base is thin. Clomiphene plus aromatase inhibitor (anastrozole) is sometimes used in men with high estradiol despite clomiphene monotherapy. The benefit over clomiphene alone is debatable and the side effect burden increases. Clomiphene plus standard nutritional support (vitamin D, zinc, omega-3) is uncomplicated. Clomiphene does not stack well with TRT. The two are alternatives, not complements: TRT suppresses the HPT axis that clomiphene is trying to upregulate. Dosing timing: morning dosing is conventional in men. In women, the cycle-day 5 to 9 protocol is the standard. ## Practical notes Clomiphene is prescription-only in essentially all jurisdictions. Generic clomiphene citrate is inexpensive (under 30 USD per cycle for standard fertility use). Enclomiphene-only formulations require compounding and are typically 50 to 150 USD per month. Quality is reliable from licensed pharmacies. The compounded enclomiphene supply varies; PCAB-certified compounders provide more reliable dosing accuracy. Baseline labs before starting in men: total and free T, LH, FSH, estradiol, prolactin, hematocrit, lipid panel, PSA (men over 40). Recheck at 8 to 12 weeks. If testosterone has not risen meaningfully, the patient may have primary (testicular) rather than secondary hypogonadism, in which case clomiphene will not work and TRT is the appropriate alternative. The honest framing for the male use case: clomiphene is a reasonable alternative to TRT in men with secondary hypogonadism who want to preserve fertility or avoid exogenous androgens. It works in roughly 60 to 80% of secondary hypogonadism cases. It does not work in primary hypogonadism. The mood side-effect profile is real and is the main practical limitation; enclomiphene-only formulations mitigate this. Monitor visual symptoms and discontinue immediately if they appear. The trial evidence supports the testosterone-elevation surrogate; long-term outcome data (CV, bone, mortality) are thinner than for TRT.